Mucopolysaccharidosis Type II (Hunter Syndrome, MPS II)

Anesthesia Implications

Clinically reviewed by anesthesia providers · Updated July 28, 2026

Difficult AirwayVideo LaryngoscopeC-spineCareful PositioningCopious SecretionsReactive AirwayBronchospasm riskAspirationIncreased ICPArrhythmiasPulmonary HypertensionAvoid HypoxiaAvoid OpioidsReduced Cardiac OutputObstructive Sleep ApneaRestrictive Lung DiseaseValvular Heart Disease

Pathophysiology

Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is an X-linked recessive lysosomal storage disease caused by deficient iduronate 2-sulfatase, the first enzyme in the breakdown of heparan and...

Read the full condition post with a free account

Free. It opens every drug, surgery and condition in the library.

Already have an account?

Master Anesthesia

Master Anesthesia

Mucopolysaccharidosis Type II (Hunter Syndrome, MPS II)

Pathophysiology

Read the full condition post with a free account